| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 26 May 2025 | 16 May 2025 |
| Aurobindo Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2025 inter alia to consider and approve Intimation of Board meeting to be held on May 26 2025 to consider Audited Financial Results for the fourth quarter and financial year ended March 31 2025. Intimation of appointment of Secretarial Auditors (As Per BSE Announcement dated on 26.05.2025) | ||
| Board Meeting | 6 Feb 2025 | 17 Jan 2025 |
| AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2025 inter alia to consider and approve Intimation of Board Meeting to be held on February 6 2025 to consider and approve inter alia the standalone and consolidated Unaudited financials results of the company for the third quarter and Nine months period ended December 312024 Intimation of outcome of the Board meeting held on February 6, 2025 (As Per Bse Announcement Dated on 06.02.2025) | ||
| Board Meeting | 9 Nov 2024 | 1 Nov 2024 |
| AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2024 inter alia to consider and approve Intimation of Board meeting to be held on Saturday November 9 2024 to consider and approve inter alia the Standalone & Consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30 2024. In accordance with the provisions of Regulations 30 and all other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the Company at its meeting held today, November 9, 2024, has inter alia, considered and approved the standalone and consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2024, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Reports issued by the Statutory Auditors. (As Per BSE Announcement Dated on 09.11.2024) Submitting the corrigendum to the unaudited financial results for the quarter and half year ended 30.09.2024. (As Per BSE Announcement Dated on 10.11.2024) In accordance with the provisions of Regulations 30 and all other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the Company at its meeting held today, November 9, 2024, has inter alia, considered and approved the standalone and consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2024, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Reports issued by the Statutory Auditors. (As Per BSE Announcement Dated on: 09/11/2024) | ||
| Board Meeting | 10 Aug 2024 | 31 Jul 2024 |
| AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2024 inter alia to consider and approve Intimation of Board Meeting to be held on August 10 2024 to consider and approve interalia the financial results for the first quarter ended June 30 2024. Submission of outcome of Board meeting (As Per BSE Announcement Dated on: 10/08/2024) | ||
| Board Meeting | 18 Jul 2024 | 14 Jul 2024 |
| AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/07/2024 inter alia to consider and approve A meeting of the Board of Directors of the Company will be held on Thursday July 18 2024 to consider inter alia a proposal for buyback of the fully paid-up equity shares of the Company and the matters necessary and incidental thereto in accordance with the applicable provisions under the Companies Act 2013 the Securities and Exchange Board of India (Buy-back of Securities) Regulations 2018 and other applicable laws Intimation of outcome of Board meeting where the Board has approved buyback of equity shares of the Company. (As per BSE Announcement Dated on 18/07/2024) | ||
Here are some of the stocks that may see significant price movement today: Lupin, IndiGo, Nazara Tech, Aurobindo Pharma, etc.
Annual income at the company also grew by a big margin of ₹31,724 crore in FY25 from ₹29,002 crore in FY24, up 9.4% on yearly basis
Here are some of the stocks that may see significant price movement today: Gensol Engineering, Oberoi Realty, TVS Motor Company, etc.
Aurobindo Pharma is going to launch Dasatinib in Q1 FY26, which will be in line with its plans to enhance its oncology portfolio in the US generics market.
Following the audit, the US FDA issued a Form 483 with 11 observations at closure, which Aurobindo Pharma described as small procedural observations.
Here are some of the stocks that may see significant price movement today: GAIL, Zydus Lifesciences, Aurobindo Pharma, etc.
As per the company, the drug functions by blocking a protein called RANKL, which is responsible for breaking down bone tissue.
Here are some of the stocks that may see significant price movement today: BHEL, Coromandel International, Aurobindo Pharma, etc.
As per the company’s filing with the bourses, the inspection was concluded with five procedural observations.
Revenue increased by 8.5% YoY to ₹7,978.5 crore.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
